



PRESS RELEASE • PRESS RELEASE • PRESS RELEASE

## Neovacs to participate in two upcoming investor events in the United States and France

Company to conduct investor meetings at LifeSci Advisors Corporate Access Event in San Francisco, CA and Present at Biomed Event 2017 in Paris, France

**Paris and Boston, January 6<sup>th</sup>, 2017 - NEOVACS (Alternext Paris: ALNEV)**, leader in active immunotherapy for the treatment of autoimmune diseases, today announced that Neovacs will participate in two upcoming investor events in the United States and France.

Neovacs will be participating in the LifeSci Advisors Corporate Access Event, hosting one-on-one meetings with investors January 9-11 at the Sir Francis Drake Hotel in San Francisco, CA. This event is being held around the **35<sup>th</sup> Annual J.P Morgan Healthcare Conference**.

Neovacs will present a corporate overview at the **Biomed Event - 2nd edition - on January 26 at the Salon Hoche in Paris, France**. This event is being sponsored by **Invest Securities**, and brings together leading biotechnology-focused European institutional investors and leading European biotechnology companies.

Neovacs' management team is available to meet with investors at both events. To request a meeting, please send an email to: [contact@neovacs.com](mailto:contact@neovacs.com).

### About Neovacs

Listed on Alternext Paris since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFN $\alpha$ -Kinoid, an immunotherapy being developed for the indication of lupus, dermatomyositis and also in preclinical trial for Type 1 diabetes. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.  
[www.neovacs.fr](http://www.neovacs.fr)

### Contacts

**NEOVACS – Corporate Communications & Investor Relations**

**Charlène Masson**

+33 (0)1 53 10 93 00

[cmasson@neovacs.com](mailto:cmasson@neovacs.com)

**LIFESCI ADVISORS- Investor Relations / Financial Communications**  
**Chris Maggos**  
[chris@lifesciadvisors.com](mailto:chris@lifesciadvisors.com)